成人结缔组织病患者二尖瓣修复术的耐久性
本研究回顾单中心2012至2023年因疑似或确诊Marfan、Loeys-Dietz及Ehlers-Danlos综合征接受二尖瓣修复术的29例成人患者,并与同期1757例退行性二尖瓣反流行首次孤立二尖瓣修复术患者比较。结果显示两组30天生存率无差异,中期生存无差异,结缔组织病组无再干预或显著反流复发,提示二尖瓣修复术安全且耐久。
要点
- 结缔组织病患者二尖瓣修复术后30天生存率96.6%,与退行性反流组98.0%无差异。
- 结缔组织病组中期生存与退行性反流组无差异,随访期间无再干预或显著反流复发。
- 二尖瓣修复术应被视为结缔组织病患者的标准治疗。
核心结论
- 二尖瓣修复术在结缔组织病患者中可安全实施,短期和中期生存良好,耐久性优异。
- 二尖瓣修复术应被视为结缔组织病患者的标准治疗。
研究设计与样本
- 单中心数据库回顾性研究,纳入2012至2023年因疑似或确诊Marfan、Loeys-Dietz及Ehlers-Danlos综合征接受二尖瓣修复术的29例成人患者。
- 对照组为同期因退行性二尖瓣反流接受首次孤立二尖瓣修复术的1757例患者。
主要发现
- 结缔组织病组83%(24/29)患者修复后即刻二尖瓣反流小于微量。
- 两组30天生存率无差异(结缔组织病组96.6% vs 退行性反流组98.0%;P = .411)。
- 两组中期生存无差异(P = .586)。
- 结缔组织病组中位超声随访3.5年(四分位距1.1-6.1年),末次随访时无患者需二尖瓣再干预或出现显著二尖瓣反流复发。
临床怎么用
- 对结缔组织病合并二尖瓣病变的成人患者,二尖瓣修复术可作为标准治疗选择。
- 术后中期需超声随访监测反流复发,但本研究显示再干预率低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Connective tissue diseases (CTDs) are known risk factors for the development of mitral valve disease. Despite this risk, mitral valve repair (MVr) in patients with CTD remains underused. This study sought to investigate the survival and durability of MVr in adult patients with CTD. METHODS: All patients with suspected or confirmed Marfan, Loeys-Dietz, and Ehlers-Danlos syndromes who underwent MVr at a single institution between 2012 and 2023 were identified through database review. Survival of this cohort was compared with survival in patients with degenerative mitral regurgitation (MR) who underwent first-time isolated MVr during the same period. Primary end points included 30-day mortality, predicted intermediate-term survival evaluated with Kaplan-Meier analysis, recurrent moderate or severe MR, and rate of mitral reintervention. RESULTS: A total of 29 patients with CTD and 1757 patients with degenerative MR underwent MVr. Notably, 83% (24 of 29) of patients with CTD had less than trivial MR immediately after repair. No difference in 30-day survival was observed between the groups (CTD 96.6% vs degenerative MR 98.0%; P = .411). Similarly, there was no difference in intermediate-term survival (P = .586). Median echocardiographic follow-up time for patients with CTD was 3.5years (interquartile range, 1.1-6.1 years), and none required mitral valve reintervention or experienced recurrence of significant MR at the last known follow-up. CONCLUSIONS: MVr can safely be performed in patients with CTD, with good short- and intermediate-term survival, as well as excellent durability. MVr should be considered a standard of care in patients with connective tissue disease.
引用
- Kazaleh M, Wagner C, Patil R, et al. Durability of Mitral Valve Repair in Adult Connective Tissue Disease. Ann Thorac Surg. 2026. PMID: 41997522. doi:10.1016/j.athoracsur.2026.03.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。